Drug Profile
Research programme: CNS disorder therapeutics - Promentis Pharmaceuticals
Alternative Names: Antioxidants - Promentis Pharmaceuticals; Glutamate signalling modulators - Promentis PharmaceuticalsLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Marquette University; Promentis Pharmaceuticals; University of Wisconsin at Milwaukee
- Developer Promentis Pharmaceuticals
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action Antioxidants; Glutamate receptor modulators; SLC7A11 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease; Pervasive child development disorders; Psychiatric disorders; Schizophrenia
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Psychiatric-disorders in USA
- 28 Jul 2018 No recent reports of development identified for research development in Pervasive-child-development-disorders in USA
- 30 Mar 2017 Preclinical trials in Psychiatric disorders in USA (unspecified route)